Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 32

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

272

HTML

2646

Figures (1-7)

237

Tables (1-1)

184

Sum=3339

Aug 28, 2005 (publication date) through Nov 11, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Aug 28, 2005; 11(32): 4931-4938
Published online Aug 28, 2005. doi: 10.3748/wjg.v11.i32.4931

Table 1 Serum biochemical parameters, body, and liver weight in the different experimental groups (mean±SD)

^aP<0.05 vs BDL,

^bP<0.01 vs Sham.

Citation: Marra F, DeFranco R, Robino G, Novo E, Efsen E, Pastacaldi S, Zamara E, Vercelli A, Lottini B, Spirli C, Strazzabosco M, Pinzani M, Parola M. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J Gastroenterol 2005; 11(32): 4931-4938
URL: https://www.wjgnet.com/1007-9327/full/v11/i32/4931.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i32.4931